
Results
2
Large Cap Companies that analysts expect to have high earnings, revenue or cash flow growth in the next 3 years.
2 companies
argenx
Market Cap: €38.7b
A commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.
ARGX
€632.60
7D
-1.5%
1Y
17.0%
UCB
Market Cap: €48.3b
A biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.
UCB
€253.80
7D
-3.5%
1Y
40.2%